e-SPACE Heart Failure 2022
Published: 19 October 2022
Part 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
Part 1 | Session 1 Plenary Session 1: Implementing the 4 foundational therapies in clinical practice John J Atherton, Piotr Ponikowski, Mark Petrie, Gianluigi Savarese, Kieran Docherty
Part 1 | Session 2 Meet the expert: Emerging evidence across the spectrum of heart failure: new insights from the deliver trial (Supported by an educational grant from AstraZeneca) John JV McMurray, Rudolf A. de Boer
Part 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1) Yuhui Zhang, David Sim, Giuseppe Rosano, Vijay Chopra, Béla Merkely, A John Camm
Part 1 | Session 4 Meet the expert: SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Maurizio Volterrani, Anja Sandek
Part 1 | Session 6 Plenary Session 3: Using SGLT2 in your patients: practical considerations Philippe Gabriel Steg, Shelley Zieroth, Milton Packer, Muthiah Vaduganathan, Cecilia Bahit , Subodh Verma
Part 1 | Session 7 Satellite Symposium: SGLT2 inhibition as foundational heart failure therapy: have we changed our practices? (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Andrew JS Coats, Shelley Zieroth, Stefan Anker, Daniela Tomasoni, Clara Saldarriaga
Part 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2) Giuseppe Galati, Altamash Y. Shaikh, Ewa Jankowska, George L Bakris, Stephan Von Haehling, Javed Butler
Part 1 | Session 9 Meet the expert: Best practice recommendations for the management of hyperkalemia (Supported by an educational grant from AstraZeneca) Clara Bonanad Lozano , Aaron Wong
Part 1 | Session 10 Meet the expert: Hyperkalaemia in patients with heart failure – dreadful side effect or manageable condition? (Supported by an unrestricted educational grant from CSL Vifor) Javed Butler, Ileana L Piña
Part 1 | Session 11 Plenary Session 5: Managing side effects of HF drugs Mitja Lainscak, Ambarish Pandey, Faiez Zannad, Justin Ezekowitz, Ileana L Piña, Harriette Van Spall
Part 1 | Session 12 Meet the expert: Sex differences in advanced heart failure Andrew JS Coats, Aditi Nayak
Part 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF Antonio Ceriello, Naveed Sattar, Stefan Anker, Tammy Lyn Kindel, Andrew JS Coats, Jean-Philippe Minart
Part 2 | Session 1 Plenary Session 7: New technologies to manage your patients Vijay Chopra, Rishi Sethi, Friedrich Koehler, Jasper J Brugts, William T Abraham, Leor Perl
Part 2 | Session 2 Meet the expert: Unlocking the potential of baroreflex activation therapy (BAT) for HFrEF patients (Sponsored by an unrestricted grant from CVRx) Stefan Anker, Marat Fudim
Part 2 | Session 3 Plenary Session 8: New technologies to treat your patients Sajid Ansari, Fadi Jouhra, Marat Fudim, Johann Bauersachs, William T Abraham, Thomas Thum
Part 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines Stefan Anker, Paul A Heidenreich, Antoni Bayés-Genís, Biykem Bozkurt, Gerasimos Filippatos, John GF Cleland
Part 2 | Session 5 Satellite Symposim: Bridging the implementation gap in heart failure across the EF spectrum (Supported by an educational grant from AstraZeneca) John JV McMurray, Biykem Bozkurt, Giuseppe Rosano, Stephen J Greene
Part 2 | Session 6 Plenary Session 10: How to implement these GLS in ambulatory patients around the world Katherine Tuttle, Mehmet Birhan Yilmaz, Petar M Seferovic, Sivadasanpillai Harikrishnan, Yuhui Zhang, Magdy Abdelhamid , Clara Saldarriaga, Hiroyuki Tsutsui
Part 2 | Session 7 Meet the expert: SGLT2 inhibition in patients with HFrEF ‒ a case-based discussion (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Ewa Jankowska, Daniela Tomasoni
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Stephen J Greene
Professor of Medicine, Professor of Population Health Sciences and Policy, and Director of Academic Affairs
Dr Stone is a leading expert in interventional cardiology and is one of the most widely cited researchers in science. He has served as the principal investigator for approximately 130 national and international multicentre randomised trials, has delivered thousands of lectures internationally, and has authored more than 2,500 book chapters, manuscripts and abstracts published in peer-reviewed literature.
Dr Stone is the Director of Academic Affairs for Mount Sinai Heart Health System, and Professor of Medicine and Professor of Population Health Sciences and Policy at The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine, at Mount Sinai, New York.
Dr Gregg Stone is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3).
Dr Horst Sievert, MD, is the Director of the CardioVascular Center Frankfurt, Sankt Katharinen, and the Department of Internal Medicine, Cardiology, and Vascular Medicine of the Sankt Katharinen Hospital in Frankfurt, Germany.
Dr Sievert is also an Associate Professor of Internal Medicine/Cardiology at the University of Frankfurt. Dr Sievert became Director of the Department of Interventional Cardiology and Angiology of the Heart Center Rotenburg in 1990, Senior Consultant at the Bethanien Hospital in Frankfurt in 1993, and Director of the CardioVascular Center Frankfurt, Sankt Katharinen in 2003. He has been the principal investigator in a number of clinical trials and has authored more than 130 manuscripts and 500 abstracts in peer-reviewed journals and 50 books and book contributions.
Ralph von Bardeleben
Head of the Centre of Structural Heart Disease Interventions and the Heart Valve Centre
Prof Ralph Stephan von Bardeleben is the Head of the Centre of Structural Heart Disease Interventions and the Heart Valve Centre in Mainz, Germany.
Prof Bardeleben is Past-President of the German working group on Echocardiography of the German Society of Cardiology and a member of several medical societies. He serves on the Clinical Program commission and at your region program of the ESC and is a reviewer for several peer-reviewed journals. Newly elected co-editor-in-chief of Echocardiography Journal.
He participates as PI, steering committee member and core laboratory in several medical device trials, including a German Federal Institute for Drugs and Medical Devices (BfArM)-approved first- or early-in-human medical device implant trials.